Methods for early detection of cancer
Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
1. A method for enriching polynucleotides obtained or derived from cell-free deoxyribonucleic acid (cfDNA) molecules from a sample of a subject, comprising:
contacting the polynucleotides with a sequencing panel to generate an enriched population of polynucleotides, wherein the sequencing panel comprises oligonucleotide probes comprising nucleotides that hybridize to one or more differentially methylated regions of the polynucleotides, wherein the one or more differentially methylated regions comprise at least one genomic region that is abnormally methylated in at least one specific cancer type, wherein the cancer type is ovarian cancer, pancreatic cancer, breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC), or liver cancer,
wherein the oligonucleotide probes are tiled across one or more of the differentially methylated regions with a depth of at least 2×.
2. The method of claim 1 , wherein the depth of the probes is at least 3×.
3. The method of claim 1 , wherein the sequencing panel comprises a subpanel of markers for identifying tissue of origin.
4. The method of claim 3 , wherein the markers are tissue-specific epigenetic markers.
5. The method of claim 1 , wherein a plurality of the oligonucleotide probes is selected using information from whole-genome bisulfate sequencing including from tumor samples.
6. The method of claim 1 , wherein the oligonucleotide probes are about 60 nucleotides to about 120 nucleotides in length.
7. The method of claim 1 , wherein the sequencing panel is at least 150 kilobases (kb).
8. The method of claim 1 , wherein the polynucleotides are ligated to adapters prior to the contacting of the polynucleotides with the sequencing panel.
9. The method of claim 1 , wherein the at least one genomic region is a transcription start site in a promoter region of a tumor suppressor gene.
10. The method of claim 1 , wherein the sequencing panel comprises one or more regions from a plurality of genes, including AKT1, ALK, APC, ATM, BRAF, CTNNB1 EGFR, ERBB2, ESR1, FGFR2, GAT A3, GNAS, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, PTEN, RB1, SMAD4, STK11, and TP53.
11. The method of claim 1 , wherein the oligonucleotide probes are biotinylated.
12. The method of claim 1 , wherein the subject does not have a cancer that is detectable by imaging methods.
13. The method of claim 1 , further comprising sequencing a plurality of enriched polynucleotides to generate sequencing reads.
14. The method of claim 13 , wherein the sequencing is performed within a read budget that allocates a pre-determined total number of base reads, wherein the plurality of enriched polynucleotides comprises no more than a pre-determined amount of DNA.
15. The method of claim 13 , wherein the sequencing comprises sequencing at least 1 million base pairs.
16. The method of claim 13 , wherein the enriched polynucleotides are amplified prior to the sequencing.
17. The method of claim 13 , further comprising detecting a cancer at a sensitivity of about 80% or greater.
18. The method of claim 13 , further comprising detecting a genetic variant, wherein the genetic variant is a single nucleotide variant (SNV), an insertion or deletion (indel), and gene fusion, or a copy number variation (CNV).
19. A sequencing panel, comprising:
oligonucleotide probes comprising nucleotides that hybridize to one or more differentially methylated regions of polynucleotides obtained or derived from a sample of cell-free deoxyribonucleic acid (cfDNA) molecules, wherein the one or more differentially methylated regions comprise at least one genomic region that is abnormally methylated in at least one specific cancer type, wherein the cancer type is ovarian cancer, pancreatic cancer, breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC), or liver cancer,
wherein the oligonucleotide probes are tiled across one or more of the differentially methylated regions with a depth of at least 2×.
20. The sequencing panel of claim 19 , wherein the depth of the probes is at least 3×.
21. The sequencing panel of claim 19 , further comprising a subpanel of markers for identifying tissue of origin.
22. The sequencing panel of claim 21 , wherein the markers are tissue-specific epigenetic markers.
23. The sequencing panel of claim 19 , wherein a plurality of the oligonucleotide probes is selected using information from whole-genome bisulfite sequencing including from tumor samples.
24. The sequencing panel of claim 19 , wherein the oligonucleotide probes are about nucleotides to about 120 nucleotides in length.
25. The sequencing panel of claim 19 , wherein the sequencing panel is at least 150 kilobases (kb).